Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Sponsor: Changhai Hospital
Summary
pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-11-30
Completion Date
2026-11-29
Last Updated
2023-12-06
Healthy Volunteers
No
Conditions
Interventions
Surufatinib
Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Placebo
Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Locations (1)
Changhai Hospital
Shanghai, China